CYSTIC FIBROSIS FOUNDATION AWARDS $21 MILLION TO VERTEX.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has expanded its
drug discovery and development collaboration with Cystic Fibrosis
Foundation Therapeutics, Inc. (CFFT), the nonprofit drug . . .
ELBIT REPORTS FIRST QTR 2004 REVENUES INCREASED
36%.(finance)
Elbit Medical Imaging Ltd. (NASDAQ:EMITF) ("EMI" or the
"company"), Tel Aviv, Isrel, has announced its consolidated
results for the quarter ended March 31, 2004.
Net profit for the first quarter . . .
AVAX REPORTS REVENUE INCREASES 52% OVER PRIOR
YEAR.(finance)
AVAX Technologies, Inc. (BULLETIN BOARD: AVXT), Philadelphia, has
announced financial results for the first quarter ended March 31, 2004.
Net loss decreased for the three-month period ended March . . .
MEDIMMUNE TO ACHIEVE $2 BILLION IN REVENUES BY
'09.(goals)(Brief Article)
At its annual meeting of shareholders held in Gaithersburg,
Maryland, MedImmune, Inc. (NASDAQ:MEDI) provided an update on its
corporate progress to its investors, and reiterated its 2004 . . .
INYX REPORTS FIRST QTR '04 NET LOSS OF $1.9
MILLION.(financial results)
Inyx, Inc., New York, (BULLETIN BOARD: IYXI) , an emerging
specialty pharmaceutical company with a focus on niche aerosol drug
delivery technologies and products, has announced that it had filed . . .
SYMYX REPORTS FIRST QTR 2004 REVENUE OF $19.5 MILLION.(Brief
Article)
Symyx Technologies, Inc. (Nasdaq:SMMX), Santa Clara, Calif., has
reported financial results for the first quarter ended March 31, 2004.
Revenue for the quarter was $19.5 million compared with . . .
ORPHAN MEDICAL REPORTS $5.4 MILLION REVENUE FOR FIRST QTR
2004.(Brief Article)
Orphan Medical, Inc. (Nasdaq:ORPH), Minneapolis, has announced
results for the first quarter ended March 31, 2004. Revenue for the
quarter was $5.4 million, which includes $1 million of . . .
BOSTON SCIENTIFIC FIRST QTR 2004 NET INCOME INCREASES
100%.
Boston Scientific Corporation (NYSE:BSX), Natick, Mass., has
announced financial results for its first quarter ended March 31, 2004,
as well as preliminary information related to U.S. sales of . . .
SEROLOGICALS FIRST QTR 2004 REVENUES UP 66%.
Serologicals Corporation, Atlanta, (NASDAQ:SERO) has announced
financial results for the first quarter 2004.
"The first quarter of 2004 was marked by several significant
accomplishments which . . .
VERIDIEN PROJECTS FIRST QTR 2004 PROFIT.(Veridien Corp. )
Veridien Corporation (OTCBB:VRDE), St Petersburg, Fla., projects
positive quarterly EBITDA and profitability in the first quarter, 2004.
The company continues to work diligently to do the . . .
$40-50 MILLION IN CUBICIN SALES PROJECTED FOR 2004.(Cubist
Pharmaceuticals Inc.)
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) has provided updated
information on the launch of its flagship product, Cubicin (daptomycin
for injection). CUBICIN was launched in November 2003 in the . . .
MEDMIRA REPORTS 2ND QTR NET LOSS OF $996 THOUSAND.
MedMira Inc., (TSX Venture: MIR), Halifax, Nova Scotia, has
announced its financial results for the three-month period ending
January 31, 2004.
Unit sales were up 2% over the previous quarter, . . .
HAEMACURE REPORTS $1.06 MILLION NET CONSOLIDATED LOSS.
For the first quarter ended January 31, 2004, Haemacure Corporation
(TSX:HAE), Montreal, recorded sales of $1.22 million, compared with
$5.34 million for the first quarter of fiscal 2003. This . . .
MEDIMMUNE PLANS TO ACHIEVE $2 BILLION IN REVENUES BY
2009.(financial plans)
MedImmune, Inc. (NASDAQ:MEDI), Gaithersburg, Md., expects to
achieve $2 billion in total revenues by 2009, driven by investments in
its pipeline and the continued growth of its currently . . .
NORTH AMERICAN SCIENTIFIC 1ST QTR NET SALES DECREASE 35%.
North American Scientific, Inc. (NASDAQ: NASI), Chatsworth, Calif.,
has announced financial results for its first quarter ended January 31,
2004.
For the first quarter ended January 31, 2004, the . . .
MONSANTO'S SEEDS/TRAITS EXPECTED TO DRIVE MID-TERM
GROWTH.(Monsanto Co. Agricultural Group)
Significant growth in Monsanto's seeds and traits business is
expected to drive the company's mid-term growth, according to Hugh
Grant, chairman, president and chief executive officer. . . .
APPLIED BIOSYSTEMS REPORTS 2ND QTR FISCAL 2004 EPS OF 25
CENTS.(Revenue data)
Applied Biosystems Group (NYSE:ABI), Foster City, Calif., an
Applera Corporation business, has reported that earnings per share were
$0.25 for the second quarter of fiscal 2004, compared to $0.14 . . .
AGILENT EXPECTS TO EXCEED GUIDANCE FOR 1ST QTR RESULTS.(Brief
Article)
Agilent Technologies Inc. (NYSE:A), Palo Alto. Calif. expects its
results for the first fiscal quarter, ending Jan. 31, 2004, to be above
the guidance provided in early December.
First quarter . . .
MEDICIS REPORTS 2ND QTR FISCAL 2004 NET REVENUES OF $70.6
MIL.
Medicis (NYSE:MRX), Scottsdale, Ariz., has announced second quarter
fiscal 2004 net revenues of $70.6 million with "if- converted"
net income of $16.0 million, or $0.25 per diluted share, absent a . . .
2003 BIOTECH'S 2ND BEST YEAR AND 2004 LOOKS BETTER.
"Rising like a phoenix from the ashes, the biotech industry
re-emerged in 2003 recovering from the massive devaluation that took
place during the last three years," said G. Steven Burrill, CEO . . .
|
|